Immatics’ cell therapy leapfrogs into phase 3 on strength of early-stage survival data
Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of its melanoma cell therapy IMA203 this year in light of the response and progression-free survival (PFS) results seen in a phase 1b study.